Armata Pharmaceuticals Secures $2.5M DoD Boost for Phage Therapy

The capital is earmarked for key activities required to push AP-SA02, a bacteriophage cocktail designed to treat complicated Staphylococcus aureus bacteremia, toward a pivotal Phase 3 superiority study. Armata plans to initiate this trial in the second half of 2026, targeting both methicillin-sensitive and methicillin-resistant infections. CEO Dr. Deborah Birx noted that the federal support is critical to advancing phage therapy as a viable tool against rising antimicrobial resistance.

AP-SA02 currently holds both Fast Track and Qualified Infectious Disease Product designations from the FDA. The program’s momentum follows positive results from the Phase 2a diSArm study, which were presented at IDWeek 2025. By maintaining in-house manufacturing capabilities, the Los Angeles-based firm aims to bridge the gap between clinical development and commercialization for military and civilian patients alike.